Auris Medical Holding (EARS) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Auris Medical Holding (EARS) Announces Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
November 28, 2017 6:42 AM ESTHEALOS trial did not meet primary efficacy endpoint in overall study populationClinically and statistically significant improvement in subpopulation of patients with profound acute hearing loss Conference call scheduled for today to review HEALOS data, provide a business update and present third quarter 2017 financial results
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced top-line results from the HEALOS Phase 3 clinical trial of AM-111 in severe to profound sudden... More
